Ciloxan Ophthalmic Solution
"Researchers at the National Eye Institute (NEI) have found a unique cell type that, in tests on mice, can protect against uveitis—a group of inflammatory diseases that affect the eye and can cause vision loss.
Uveitis occurs when "...
Ciloxan Ophthalmic Solution
Systemic Absorption: A systemic absorption study was performed in which CILOXAN Ophthalmic Solution was administered in each eye every two hours while awake for two days followed by every four hours while awake for an additional 5 days. The maximum reported plasma concentration of ciprofloxacin was less than 5 ng/mL. The mean concentration was usually less than 2.5 ng/mL.
Microbiology: Ciprofloxacin has in vitro activity against a wide range of gram-negative and gram-positive organisms. The bactericidal action of ciprofloxacin results from interference with the enzyme DNA gyrase which is needed for the synthesis of bacterial DNA. Ciprofloxacin has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections (SEE INDICATIONS AND USAGE section):
Streptococcus (Viridans Group)
Ciprofloxacin has been shown to be active in vitro against most strains of the following organisms, however, the clinical significance of these data is unknown:
Enterococcus faecalis (Many strains are only moderately susceptible)
|Acinetobacter calcoaceticus||Escherichia coli||Proteus mirabilis|
|subsp. anitratus||Haemophilus ducreyi||Proteus vulgaris|
|Aeromonas caviae||Haemophilus parainfluenzae||Providencia rettgeri|
|Aeromonas hydrophila||Kiebsiella pneumoniae||Providencia stuartii|
|Brucella melitensis||Klebsiella oxytoca||Salmonella enteritidis|
|Campylobacter coli||Legionella pneumophila||Salmonella typhi|
|Campylobacter jejuni||Moraxella (Branhamella)||Shigella sonneii|
|Citrobacter diversus||catarrhalis||Shigella flexneri|
|Citrobacter freundii||Morganella morganii||Vibrio cholerae|
|Edwardsiella tarda||Neisseria gonorrhoeae||Vibrio parahaemolyticus|
|Enterobacter aerogenes||Neisseria meningitidis||Vibrio vulnificus|
|Enterobacter cloacae||Pasteurella multocida||Yersinia enterocolitica|
Most strains of Pseudomonas cepacia and some strains of Pseudomonas maltophilia are resistant to ciprofloxacin as are most anaerobic bacteria, including Bacteroides fragilis and Clostridium difficile .
The minimal bactericidal concentration (MBC) generally does not exceed the minimal inhibitory concentration (MIC) by more than a factor of 2. Resistance to ciprofloxacin in vitro usually develops slowly (multiple-step mutation).
Ciprofloxacin does not cross-react with other antimicrobial agents such as beta-lactams or aminoglycosides; therefore, organisms resistant to these drugs may be susceptible to ciprofloxacin.
Following therapy with CILOXAN Ophthalmic Solution (ciprofloxacin hcl ophthalmic solution) , 76% of the patients with corneal ulcers and positive bacterial cultures were clinically cured and complete re-epithelialization occurred in about 92% of the ulcers. In 3 and 7 day multicenter clinical trials, 52% of the patients with conjunctivitis and positive conjunctival cultures were clinically cured and 70-80% had all causative pathogens eradicated by the end of treatment.
Last reviewed on RxList: 3/28/2006
This monograph has been modified to include the generic and brand name in many instances.
Additional Ciloxan Ophthalmic Solution Information
Ciloxan Ophthalmic Solution - User Reviews
Ciloxan Ophthalmic Solution User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.